A novel mechanism underlying drug resistance in chronic epilepsy

Annals of Neurology

Volumn 53, Issue 4, 2003, Pages 469-479

  Remy, Stefan ^a   Gabriel, Siegrun ^b   Urban, Bernd W ^a   Dietrich, Dirk ^a   Lehmann, Thomas N ^b   Elger, Christian E ^a   Heinemann, Uwe ^b   Beck, Heinz ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; SODIUM CHANNEL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; INFANT; NONHUMAN; PATCH CLAMP; PATHOGENICITY; PRIORITY JOURNAL; RAT; TEMPORAL LOBE EPILEPSY;

ADULT; ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; EPILEPSY, TEMPORAL LOBE; HIPPOCAMPUS; HUMANS; ION CHANNEL GATING; MALE; PATCH-CLAMP TECHNIQUES; RATS; RATS, WISTAR; SODIUM CHANNELS;

EID: 0345382778     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10473     Document Type: Article

References (44)

1. Tishler DM, Weinberg KI, Hinton DR, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995;36:1-6.
2. Lazarowski A, Sevlever G, Taratuto A, et al. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol 1999;21:731-734.
3. Sisodiya SM, Lin WR, Squier MV, et al. Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet 2001;357:42-43.
4. Zhang L, Ong WY, Lee T. Induction of P-glycoprotein expression in astrocytes following intracerebroventricular kainate injections. Exp Brain Res 1999;126:509-516.
5. Schuetz JD, Connelly MC, Sun D, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999;5:1048-1051.
6. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880.
7. Spratt BG. Resistance to antibiotics mediated by target alterations. Science 1994;264:388-393.
8. Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature 2000;406:775-781.
9. Brodie MJ. Do we need any more new antiepileptic drugs? Epilepsy Res 2001;45:3-6.
10. Brodie MJ, Porter RJ. New and potential anticonvulsants. Lancet 1990;336:425-426.
11. Owen A, Pirmohamed M, Tettey JN, et al. Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 2001;51:345-349.
12. Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-2524.
13. Ragsdale DS, Avoli M. Sodium channels as molecular targets for antiepileptic drugs. Brain Res Brain Res Rev 1998;26:16-28.
14. Denac H, Mevissen M, Scholtysik G. Structure, function and pharmacology of voltage-gated sodium channels. Naunyn Schmiedebergs Arch Pharmacol 2000;362:453-479.
15. Schwarz JR, Grigat G. Phenytoin and carbamazepine: potential-and frequency-dependent block of Na currents in mammalian myelinated nerve fibers. Epilepsia 1989;30:286-294.
16. Willow M, Gonoi T, Catterall WA. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol Pharmacol 1985;27:549-558.
17. +-dependent intrinsic bursting in the rat pilocarpine model of temporal lobe epilepsy. J Physiol 2001;532:205-216.
18. Margerison JH, Corsellis JAN. A clinical, electroencephalographic and neuropathological study of the brain in epilepsy, with particular reference to the temporal lobes. Brain 1966;89:499-530.
19. Blumcke I, Beck H, Lie AA, et al. Molecular neuropathology of human mesial temporal lobe epilepsy. Epilepsy Res 1999;36:205-223.
20. 28k in temporal lobe epilepsy. J Neurosci 2000;20:1831-1836.
21. Beck H, Ficker E, Heinemann U. Properties of two voltage-activated potassium currents in acutely isolated juvenile rat dentate gyrus granule cells. J Neurophysiol 1992;68:2086-2099.
22. Hamill OP, Marty A, Neher E, et al. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981;391:85-100.
23. + channels in hippocampal granule cells, hilar neurons and basket cells. J Physiol 2001;532:385-397.
24. +]o in human epileptic non-sclerotic and sclerotic hippocampal area CA1. Eur J Neurosci 2000;12:2039-2048.
25. +]o and field potentials in dentate gyrus and area CA1 of human epileptic hippocampus. Neurosci Lett 1998;249:91-94.
26. Turski WA, Cavalheiro EA, Schwarz M, et al. Limbic seizures produced by pilocarpine in rats: behavioural, electroencephalographic and neuropathological study. Behav Brain Res 1983;9:315-335.
27. + currents in human dentate granule cells from epileptogenic tissue. Epilepsia 1999;40:401-407.
28. + currents: quantitative distinction from phenytoin and possible therapeutic implications. Mol Pharmacol 1997;51:1077-1083.
29. + channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Mol Pharmacol 1991;40:756-765.
30. 2+ concentration in rat hippocampal slices. Exp Brain Res 1993;96:230-240.
31. + current. Comparison with the effects of phenytoin, carbamazepine, lidocaine and flumazenil. Brain Res 1991;548:41-49.
32. Lang DG, Wang CM, Cooper BR. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther 1993;266:829-835.
33. Vreugdenhil M, Wadman WJ. Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis. Epilepsia 1999;40:1512-1522.
34. Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic drugs. New York: Raven Press, 1995.
35. Friis ML, Christiansen J, Hvidberg EF. Brain concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients. Eur J Clin Pharmacol 1978;14:47-51.
36. Rambeck B, Schnabel R, May T, et al. Postmortem concentrations of phenobarbital, carbamazepine, and its metabolite carbamazepine-10,11-epoxide in different regions of the brain and in the serum: analysis of autoptic specimens from 51 epileptic patients. Ther Drug Monit 1993;15:91-98.
37. Leite JP, Cavalheiro EA. Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res 1995;20:93-104.
38. Glien M, Brandt C, Potschka H, et al. Anticonvulsant effects of the novel antiepileptic drug levetiracetam in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 2001;42(suppl 7):268.
39. Nissinen JPT, Pitkänen A. An animal model with spontaneous seizures: a new tool for testing the effects of antiepileptic compounds. Epilepsia 2000;41:136.
40. Loscher W, Rundfeldt C. Kindling as a model of drug-resistant partial epilepsy: selection of phenytoin-resistant and nonresistant rats. J Pharmacol Exp Ther 1991;258:483-489.
41. Löscher W, Rundfeldt C, Hönack D. Pharmacological characterization of phenytoinresistent amygdala-kindled rats, a new model of drug-resistant partial epilepsy. Epilepsy Res 1993;15:207-219.
42. Hönack D, Löscher W. Amygdala-kindling as a model for chronic efficacy studies on antiepileptic drugs: experiments with carbamazepine. Neuropharmacology 1989;28:599-610.
43. Jeub M, Beck H, Siep E, et al. Effect of phenytoin on sodium and calcium currents in hippocampal CA1 neurons of phenytoin-resistant kindled rats. Neuropharmacology 2002;42:107-116.
44. Potschka H, Fedrowitz M, Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001;12:3557-3560.